Summary
In a significant market movement during June 2025, Laverock Therapeutics was the subject of a vc funding. The transaction achieved a gross valuation of £6,500,000. Leading the round was Mercia Ventures, Maven Capital Partners, Norcliffe Capital, Calculus Capital, Eli lilly and company, Eos Advisory.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
Mercia Ventures
Lead Investor / Acquirer
Maven Capital Partners
Lead Investor / Acquirer
Norcliffe Capital
Lead Investor / Acquirer
Calculus Capital
Lead Investor / Acquirer
Eli lilly
Lead Investor / Acquirer
company
Lead Investor / Acquirer
Eos Advisory
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Seed prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in